EpicentRx Publishes Phase 2 Results for RRx-001 as an Anti-Mucositis Agent in Patients Receiving Radiation for Head and Neck Cancers
/PRNewswire/ -- EpicentRx, a leading edge, clinical stage biopharmaceutical company, announced the publication of Phase 2 results of the PREVLAR trial which...